A New Prescription for Heart Health Lifts Novo Nordisk's Prospects

UK health authorities approve Wegovy for cardiovascular prevention, expanding NHS access to 1.2M. Novo Nordisk launches US subscription model amid market pressure.

After a prolonged period of setbacks and significant share price depreciation, encouraging developments are finally emerging for Novo Nordisk. In a pivotal move, British health authorities have paved the way for broad reimbursement of the weight-loss injection Wegovy, though this time for an entirely different purpose. This decision grants the Danish pharmaceutical giant access to a lucrative new patient population numbering in the millions.

Strategic Shift Amid Market Pressure

Concurrently with the UK approval, Novo Nordisk is recalibrating its sales approach in the critical United States market. The company is now offering a tiered subscription model for self-paying customers through telehealth providers such as WeightWatchers and Ro:
* A three-month subscription costs $329 per month.
* An annual commitment reduces the monthly fee to $249.
* The maximum potential annual savings for patients is $1,200.

This customer retention strategy is considered essential. In the US, competitor Eli Lilly now commands an estimated 60% share of the GLP-1 drug market. Furthermore, pricing pressure is intensifying due to US political focus on drug costs and the first officially approved generic versions of semaglutid now available in India.

Broadened Access in the UK

The UK's National Institute for Health and Care Excellence (NICE) has officially recommended Wegovy for preventing heart attacks and strokes. A key aspect of this recommendation is the lowered eligibility threshold: patients with pre-existing conditions now only require a Body Mass Index (BMI) of 27 to qualify for the medication through the state-funded National Health Service (NHS). According to official estimates, this change makes approximately 1.2 million people in England eligible for the treatment.

Clinical data indicates that the cardiovascular benefits of the drug manifest even before significant weight loss occurs, suggesting a direct effect on the heart and blood vessels. The final NHS reimbursement guidelines are anticipated by the end of April, with the first English patients expected to receive the drug routinely through the service starting this summer. This expansion of the drug's indicated use provides Novo Nordisk with a powerful argument for future regulatory approvals in other markets, strengthening Wegovy's positioning beyond mere weight management.

Market Reaction and Ongoing Challenges

The news provided a welcome respite for investors on Wednesday, temporarily driving the share price up by four percent. Despite this uptick, the stock remains perilously close to its 52-week low, closing at €31.45 in the previous session. This underscores the persistent downward pressure that has seen the value decline by nearly 30% since the beginning of the year.